Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
52
|
pubmed:dateCreated |
1998-1-23
|
pubmed:abstractText |
The biological effects of platelet-derived growth factor (PDGF) are mediated by alpha- and beta-PDGF receptors (PDGFR), which have an intracellular tyrosine kinase domain and an extracellular region comprising five immunoglobulin-like domains (D1-D5). Using deletion mutagenesis we mapped the PDGF binding site in each PDGFR to the D2-D3 region. In the case of alpha-PDGFR, 125I-PDGF AA and 125I-PDGF BB bound to the full-length extracellular domain, D1-D5, and D2-D3 with equal affinity (Kd = 0.21-0.42 nM). Identical results were obtained for 125I-PDGF BB binding to beta-PDGFR mutants D1-D5 and D2-D3, establishing that D1, D4, and D5 do not contribute to PDGF binding. Monoclonal antibodies (mAb) directed against individual PDGFR Ig-like domains were used to extend these observations. The anti-D1 mAb 1E10E2 and anti-D5 mAb 2D4G10 had no effect on alpha- or beta-PDGFR function, respectively. In contrast, mAb 2H7C5 and 2A1E2 directed against D2 of the alpha- and beta-receptor, respectively, blocked PDGF binding, receptor autophosphorylation and mitogenic signaling with IC50 values of 0.1-3.0 nM. An anti-D4 mAb 1C7D5 blocked beta-receptor autophosphorylation and signaling without inhibiting PDGF binding consistent with the observation that D4 is essential for PDGFR dimerization (Omura, T., Heldin, C.-H., and Ostman, A. (1997) J. Biol. Chem. 272, 12676-12682). mAbs identified here act as potent PDGFR antagonists that can be used as research tools and potentially as therapeutic agents for the treatment of diseases involving unwanted PDGFR signaling.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
26
|
pubmed:volume |
272
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
33037-44
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:9407086-Animals,
pubmed-meshheading:9407086-Antibodies, Monoclonal,
pubmed-meshheading:9407086-Binding Sites,
pubmed-meshheading:9407086-CHO Cells,
pubmed-meshheading:9407086-Cricetinae,
pubmed-meshheading:9407086-Dimerization,
pubmed-meshheading:9407086-Immunoglobulins,
pubmed-meshheading:9407086-Mice,
pubmed-meshheading:9407086-Mice, Inbred BALB C,
pubmed-meshheading:9407086-Mutagenesis, Site-Directed,
pubmed-meshheading:9407086-Peptide Mapping,
pubmed-meshheading:9407086-Phosphorylation,
pubmed-meshheading:9407086-Receptors, Platelet-Derived Growth Factor,
pubmed-meshheading:9407086-Structure-Activity Relationship
|
pubmed:year |
1997
|
pubmed:articleTitle |
Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies.
|
pubmed:affiliation |
COR Therapeutics Inc., South San Francisco, California 94080, USA.
|
pubmed:publicationType |
Journal Article
|